TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20925517

Group type: EXPERIMENTAL
Intervention: MAF (0.5% ophthalmic solution with retention-enhancing agent)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Moxi (0.5% ophthalmic solution)
Number of subjects: 130
Study: 19544682

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac plus B vitamins (thiamine, pyridoxine, cyanocobalamin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study: 16937760

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 300
Study: 12900685

Group type: EXPERIMENTAL
Intervention: 30 min of heavy continuous running exercise at 79% of VO(2max)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Strenuous intermittent exercise (treadmill running at 60, 75, 90, and 100% VO(2max))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting control trial
Number of subjects: 6
Study: 11008908

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 69
Study: 8975169

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no ciprofloxacin)
Number of subjects: 33
Study: 1348010

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3887555

Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plain naproxen tablets
Number of subjects: 12
Study: 29373274

Group type: EXPERIMENTAL
Intervention: Ramucirumab with docetaxel
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo with docetaxel
Number of subjects: 1253
Study: 28701677

Group type: EXPERIMENTAL
Intervention: Tolvaptan in addition to conventional diuresis therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional diuresis therapy only (control group)
Number of subjects: 29
Study: 25979186

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) plus didanosine (ddI)‐EC/emtricitabine (FTC)
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) plus lamivudine‐zidovudine
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1571
Study: 24090189

Group type: EXPERIMENTAL
Intervention: Active implementation of a disease-management-programme for COPD
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Control group (non-intervention practices)
Number of subjects: 1372
Study: 21958380

Group type: EXPERIMENTAL
Intervention: Intensive self-management guidance (IG)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 162
Study: 18191455

Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive community treatment, psycho-educational multi-family groups, social skills training)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 328
Study: 16836709

Group type: EXPERIMENTAL
Intervention: Active Can configuration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lead Alone configuration
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both configurations
Number of subjects: 39
Study: 12828753

Group type: EXPERIMENTAL
Intervention: Lithium gluconate 8% ointment
Number of subjects: 288

Group type: COMPARATOR
Intervention: Ketoconazole 2% emulsion
Number of subjects: 288
Study: 10900994

Group type: EXPERIMENTAL
Intervention: Psychological therapies
Number of subjects: 90

Group type: COMPARATOR
Intervention: Self-selected treatment clients
Number of subjects: 90
Study: 8648014

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1505371

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three times daily)
Number of subjects: 100
Study: 6385278

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 24
Study: 29546280

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation during bed rest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric control diet during bed rest
Number of subjects: 10
Study: 27330150

Group type: EXPERIMENTAL
Intervention: Topical administration of 2 g tranexamic acid (TA) diluted in 200 ml of saline
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: 200 ml of saline (placebo group)
Number of subjects: 739

Group type: COMPARATOR
Intervention: No topical administration (control group)
Number of subjects: 739
Study: 24248037

Group type: EXPERIMENTAL
Intervention: Daily SMS reminder
Number of subjects: 50
Study: 24418871

Group type: EXPERIMENTAL
Intervention: Exercise (Ex, n=6)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vitamin E and Exercise (S+Ex, n=7)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vitamin E (S, n=8)
Number of subjects: 29
Study: 20529769

Group type: EXPERIMENTAL
Intervention: Candid #1 vaccine (Argentina)
Number of subjects: 946

Group type: COMPARATOR
Intervention: USA vaccine
Number of subjects: 946
Study: 18387167

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis patients
Number of subjects: 23
Study: 17036474

Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoint (Dazhui (GV 14), Jinsuo (GV 8), Fenglong (ST 40))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sodium valproate (oral administration)
Number of subjects: 100
Study: 15707013

Group type: EXPERIMENTAL
Intervention: Telmisartan (20‐80 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalapril (5‐10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Telmisartan and Enalapril
Number of subjects: 30
Study: 11526531

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (20 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9031963

Group type: EXPERIMENTAL
Intervention: Continuous low dose estradiol released from a vaginal ring (Estring)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Estriol vaginal cream (Synapause)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 165
Study: 8428468

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg) by iv infusion every 6 hrs for four doses
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 3593895

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily) in elderly subjects
Number of subjects: 17
Study: 31682137

Group type: EXPERIMENTAL
Intervention: Deprexis adjunctively to care-as-usual (n = 509)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Care-as-usual (n = 504)
Number of subjects: 1013
Study: 29300973

Group type: EXPERIMENTAL
Intervention: SCST plus in vivo community‐based training
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: SCST plus clinic‐based training
Number of subjects: 139

Group type: COMPARATOR
Intervention: Illness management control condition
Number of subjects: 139
Study: 27390049

Group type: EXPERIMENTAL
Intervention: Test formulation of pidotimod
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic modeling method
Number of subjects: 20
Study: 24899528

Group type: EXPERIMENTAL
Intervention: Hygienic-dietary recommendations (Mediterranean diet and exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22671310

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy
Number of subjects: 31
Study: 21389909

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioresorbable DES platforms
Number of subjects: 0
Study: 18401024

Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 15790616

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 4892

Group type: COMPARATOR
Intervention: Statin untreated group
Number of subjects: 4892
Study: 12920692

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF inhibitors (general)
Number of subjects: 0
Study: 10571597

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily (n=319)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 623

Group type: COMPARATOR
Intervention: Mebeverine 135 mg three times daily (n=304)
Number of subjects: 623
Study: 8916244

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (outpatient setting)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Disease-and-recovery model (inpatient setting)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral model (inpatient setting)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 38
Study: 1841578

Group type: EXPERIMENTAL
Intervention: Mitomycin (0.2 mg) applied once during trabeculectomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluorouracil (5 mg) injected subconjunctivally 10 times in 2 weeks after surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mitomycin group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluorouracil group
Number of subjects: 32
Study: 6357204

Group type: EXPERIMENTAL
Intervention: Orgotein (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30774323

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 30020256

Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test (CPT) performed 4 weeks after initiating AIT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test (CPT) performed prior to starting AIT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test (CPT)
Number of subjects: 0
Study: 26521057

Group type: EXPERIMENTAL
Intervention: Patient involvement in the design of the clinical trial
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 30
Study: 26004592

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fesoterodine 8 mg
Number of subjects: 108
Study: 22098585

Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 9
Study: 20541709

Group type: EXPERIMENTAL
Intervention: Pressure recovery adjustment of AVA
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Unadjusted AVAI
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Pressure recovery and ELI calculated at different aortic root levels
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of AVAI and ELI
Number of subjects: 1563
Study: 18824917

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (30 ppm) + glucocorticoids (2 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (nitrogen) + glucocorticoids (2 mg/kg)
Number of subjects: 15
Study: 15652879

Group type: EXPERIMENTAL
Intervention: Active rTMS (2,000 stimulations per day at 90% of motor threshold) over the left temporoparietal cortex for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS for 5 days
Number of subjects: 10
Study: 11803256

Group type: EXPERIMENTAL
Intervention: 5% ammonium lactate in W/O vehicle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% urea in W/O vehicle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3% ammonium lactate + 3% urea in W/O vehicle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% ammonium lactate + 5% urea in W/O vehicle
Number of subjects: 20

Group type: COMPARATOR
Intervention: drug‐free W/O vehicle
Number of subjects: 20
Study: 10332446

Group type: EXPERIMENTAL
Intervention: 20 mg oral paroxetine as needed 3 to 4 hours before planned intercourse (Study 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo as needed (Study 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 10 mg paroxetine daily for 3 weeks and then 20 mg paroxetine as needed for 4 weeks (Study 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo daily for 3 weeks and then placebo as needed for 4 weeks (Study 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo daily and placebo as needed (Study 2)
Number of subjects: 68
Study: 8750371

Group type: EXPERIMENTAL
Intervention: 30 U/kg ardeparin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 60 U/kg ardeparin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 U/kg ardeparin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All doses of ardeparin
Number of subjects: 18
Study: 2025191

Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: No pyloroplasty
Number of subjects: 24
Study: 6608885

Group type: EXPERIMENTAL
Intervention: Hyposensitized with D. farinae
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Hyposensitized with house dust (HD)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Non-treated patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: HD-treated patients
Number of subjects: 65
Study: 30337060

Group type: EXPERIMENTAL
Intervention: Extended LND
Number of subjects: 401

Group type: COMPARATOR
Intervention: Limited LND
Number of subjects: 401
Study: 29742189

Group type: EXPERIMENTAL
Intervention: Nutrafol® Women's Capsules (active treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 40
Study: 26875743

Group type: EXPERIMENTAL
Intervention: Generic lamotrigine product 1
Number of subjects: 35

Group type: COMPARATOR
Intervention: Generic lamotrigine product 2
Number of subjects: 35
Study: 25027424

Group type: EXPERIMENTAL
Intervention: Norvancomycin and heparin saline mixture
Number of subjects: 116

Group type: COMPARATOR
Intervention: Heparin saline
Number of subjects: 116
Study: 22318947

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg/day with a 36-h interval)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20558919

Group type: EXPERIMENTAL
Intervention: Continuation of LAM plus ADV combination therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Overlap/switch to adefovir dipivoxil (ADV) monotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Overlap/switch to ADV monotherapy
Number of subjects: 29
Study: 21418991

Group type: EXPERIMENTAL
Intervention: rhIL‐11 injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 16282505

Group type: EXPERIMENTAL
Intervention: Walking poles during 20-minute aerobic exercise for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: No walking poles during 20-minute aerobic exercise for 8 weeks (Control)
Number of subjects: 12
Study: 12110838

Group type: EXPERIMENTAL
Intervention: Venom immunotherapy (VIT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 74
Study: 9542482

Group type: EXPERIMENTAL
Intervention: DMP 728 at doses of 0.05 to 0.9 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMP 728 at doses up to 0.6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMP 728 at 0.9 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMP 728 at doses of 1.5 mg to 3.9 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMP 728 (all dose groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMP 728 (all doses)
Number of subjects: 0
Study: 15374302

Group type: EXPERIMENTAL
Intervention: 5 mg Aramexe retard
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg Hydergine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3391873

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid for 10 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (ES) 500 mg tid for 10 days
Number of subjects: 100
Study: 31755220

Group type: EXPERIMENTAL
Intervention: Early combination (entecavir plus Peg‐interferon [IFN]α‐2a co‐administration during year 1)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Late combination (addition of Peg‐IFNα‐2a for 48 weeks after 1 year of entecavir)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) monotherapy
Number of subjects: 447

Group type: COMPARATOR
Intervention: Non-antiviral treatment
Number of subjects: 447
Study: 29633918

Group type: EXPERIMENTAL
Intervention: Novel device for preoperative skin preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current techniques of skin preparation
Number of subjects: 0
Study: 27506926

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs‐TnT) reporting
Number of subjects: 1937

Group type: COMPARATOR
Intervention: Standard reporting (std‐report)
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs‐TnT) reporting among patients with troponin levels <30 ng/L
Number of subjects: 1937

Group type: COMPARATOR
Intervention: Standard reporting (std‐report) among patients with troponin levels <30 ng/L
Number of subjects: 1937
Study: 25149556

Group type: EXPERIMENTAL
Intervention: Diamond blade (Group 2, 33 eyes)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Metal blade (Group 1, 37 eyes)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 23657308

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (24 g/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (glycine, 25 g/day)
Number of subjects: 46
Study: 20734845

Group type: EXPERIMENTAL
Intervention: Combination of Mallampati test, Patila test, and ULBT test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh and Truview laryngoscopes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other criteria of DTI
Number of subjects: 0
Study: 19006471

Group type: EXPERIMENTAL
Intervention: 4 g P‐OM3 plus 40 mg rosuvastatin
Number of subjects: 48

Group type: COMPARATOR
Intervention: 40 mg rosuvastatin alone
Number of subjects: 48
Study: 16015260

Group type: EXPERIMENTAL
Intervention: Vitamin E co-supplementation with multi-drug therapy (MDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-drug therapy (MDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated leprosy patients)
Number of subjects: 0
Study: 12970290

Group type: EXPERIMENTAL
Intervention: Oral 17beta‐estradiol 2 mg combined with trimegestone 0.5 mg (E(2)+T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral 17beta‐estradiol 2 mg combined with dydrogesterone 10 mg (E(2)+D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10803797

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8658325

Group type: EXPERIMENTAL
Intervention: Laparoscopic extraperitoneal herniorrhaphy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open repair (Shouldice hernioplasty)
Number of subjects: 0
Study: 1387369

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg twice daily for 12 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6465808

Group type: EXPERIMENTAL
Intervention: V-Y pushback
Number of subjects: 62

Group type: COMPARATOR
Intervention: Langenbeck
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Langenbeck with pharyngeal flap
Number of subjects: 62
Study: 30776296

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (130 μg daily subcutaneous injections for a maximum of 9 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (identical appearing injections for a maximum of 9 weeks)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 29487948

Group type: EXPERIMENTAL
Intervention: Bio-psycho-social intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 34
Study: 27050241

Group type: EXPERIMENTAL
Intervention: High-velocity resistance training (HVRT) with 2 sessions per week in addition to regular soccer training (5 sessions per week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular soccer training (5 sessions per week)
Number of subjects: 24
Study: 25068301

Group type: EXPERIMENTAL
Intervention: Self-reporting of symptoms (experimental group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional interview method (control group)
Number of subjects: 41
Study: 22436542

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medical advice from the attending physician (Control Group)
Number of subjects: 60
Study: 20608875

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from patients with pneumococcal meningitis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from nonsurvivors (n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from survivors (n = 11)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) from control subjects (n = 10)
Number of subjects: 30
Study: 17909402

Group type: EXPERIMENTAL
Intervention: 1 unit of packed red cells (PRC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 units of packed red cells (PRC)
Number of subjects: 10
Study: 16050428

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patches (100 microg per day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 12585215

Group type: EXPERIMENTAL
Intervention: Ultra-small-particle-hybrid composite Point 4 with dentin adhesive OptiBond Solo Plus
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Moist-bonding technique
Number of subjects: 73
Study: 9649907

Group type: EXPERIMENTAL
Intervention: Maximal longitudinal relaxation velocity (RVm) measured in patients with AMI
Number of subjects: 22

Group type: COMPARATOR
Intervention: Maximal longitudinal relaxation velocity (RVm) measured in healthy control subjects
Number of subjects: 22